New Year’s resolution on liability
American Home Products granted final judicial approval on the Redux/Pondimin diet drug settlement after expiration of Supreme Court appeal deadline Jan. 2, AHP announced Jan. 10. The $4.75 bil. class action was approved Aug. 28, 2000 in district court and upheld on appeal Aug. 15, 2001...
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.